�ڰ�������

LiverMultiScan® detected earlier stages of treatable disease in patients with autoimmune hepatitis to allow tailored treatment

LiverMultiScan® has achieved nationwide payer coverage for diagnosis and management of NAFLD and other established chronic liver diseases

First patient recruited for multi-year collaborative primary sclerosing cholangitis (PSC) pediatric study using �ڰ�������’s imaging technology to help predict disease progression and guide patient management

New meta-analysis finds �ڰ�������’s non-invasive MRI biomarker cT1 is an effective alternative to biopsy for identifying patients at high risk of liver disease progression

�ڰ������� and HepQuant Announce Partnership to Bring a More Complete Picture of Liver Health

�ڰ������� Expands into Louisiana in Partnership with West Jefferson Medical Center in New Orleans, LA

�ڰ������� Announces Partnership with Datavant to Improve Clinical Trial Recruitment with Connected Data

New study finds �ڰ�������®’s LiverMultiScan® may positively impact patient participation in liver disease care pathways

First European guidance on the use of multiparametric MRI in fatty liver disease